Heparin (DrugBank: Heparin)
11 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
60 | 再生不良性貧血 | 1 |
70 | 広範脊柱管狭窄症 | 1 |
79 | 家族性高コレステロール血症(ホモ接合体) | 1 |
84 | サルコイドーシス | 1 |
107 | 若年性特発性関節炎[全身型若年性特発性関節炎(~2018.3)] | 1 |
224 | 紫斑病性腎炎 | 1 |
226 | 間質性膀胱炎(ハンナ型) | 7 |
280 | 巨大動静脈奇形(頚部顔面又は四肢病変) | 1 |
299 | 嚢胞性線維症 | 4 |
316 | カルニチン回路異常症 | 1 |
317 | 三頭酵素欠損症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01343680 (ClinicalTrials.gov) | April 2011 | 27/4/2011 | Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients | A Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, Canada | Childhood Cancer;Aplastic Anemia;Metabolic Disorders | Drug: Heparin;Drug: Normal saline | Alberta Children's Hospital | Stollery Children's Hospital | Terminated | N/A | 17 Years | Both | 2 | Phase 3 | Canada |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01522846 (ClinicalTrials.gov) | January 2012 | 9/1/2012 | Heparin Solution and INTEM/HEPTEM Analysis | Influence by Heparinized Flush Solution of the Radial Artery Catheter: INTEM and HEPTEM Analysis. | Brain Tumor;Spinal Stenosis;Cerebral Artery Anuerysm | Drug: Heparin | Seoul National University Bundang Hospital | NULL | Completed | 20 Years | N/A | Both | 25 | N/A | Korea, Republic of |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02286596 (ClinicalTrials.gov) | April 2013 | 3/11/2014 | Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia | Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | Device: heparin-induced extracorporeal LDL precipitation;Device: dextran sulfate adsorption | Laval University | NULL | Completed | 18 Years | 60 Years | Both | 9 | N/A | Canada |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000004267 | 2010/10/01 | 01/10/2010 | PET/CT finding of cardiac sarcoidosis | sarcoidosis | Give heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis. | Tokushima University Hospital | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Not selected | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-OOC-15006228 | 2015-04-01 | 2015-04-09 | Clinical and mechanism research of extracellular histone in systemic-onset juvenile idiopathic arthritis | Clinical and mechanism research of extracellular histone in systemic-onset juvenile idiopathic arthritis | systemic-onset juvenile idiopathic arthritis | disease active group,disease remission group:add heparin into neutrophils in vitro; | Shanghai Children's Medical Center | NULL | Recruiting | 3 | 16 | Both | disease active group,disease remission group:30; | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03591471 (ClinicalTrials.gov) | September 2014 | 9/12/2014 | Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment | Demonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome Differentiation | Henoch-Schönlein Purpura Nephritis | Drug: Glycosides Of Tripterygium Wilfordii Hook(GTW);Drug: Sulfotanshinone Sodium Injection;Drug: Chinese herbs based on syndrome differentiation;Drug: Prednisone Acetate Tablets;Drug: Benazepril Hydrochloride Tablets;Drug: Low Molecular Weight Heparin Calcium Injection;Drug: Dipyridamole Tab 25 MG;Drug: Chinese medicine placebo | Henan University of Traditional Chinese Medicine | Peking University First Hospital;Children's Hospital of Fudan University;Shanghai Children's Hospital;Chengdu University of Traditional Chinese Medicine;Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | Unknown status | 2 Years | 18 Years | All | 500 | Phase 1;Phase 2 | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04401176 (ClinicalTrials.gov) | July 2020 | 19/5/2020 | Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome | A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A | Walter Reed National Military Medical Center | NULL | Not yet recruiting | 18 Years | N/A | Female | 58 | Phase 2 | NULL |
2 | JPRN-UMIN000027918 | 2016/07/01 | 25/06/2017 | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis | interstitial cystitis | heparin-lidocaine intravesical therapy | Department of Urology and Renal transplantation, Nagasaki University Hospital | NULL | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan | |
3 | JPRN-UMIN000026714 | 2016/02/26 | 27/03/2017 | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. | Interstitial cystitis | Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. | Department of Urology, Mitsui Memorial Hospital | NULL | Pending | 20years-old | Not applicable | Male and Female | 20 | Phase 2;Phase 3 | Japan | |
4 | NCT02591199 (ClinicalTrials.gov) | September 2015 | 28/10/2015 | Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Urigen | NULL | Terminated | 18 Years | N/A | All | 92 | Phase 2 | United States |
5 | NCT01048177 (ClinicalTrials.gov) | December 2012 | 11/1/2010 | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | Vulvodynia | Drug: Bladder instillation with heparin/ lidocaine | Scripps Health | NULL | Withdrawn | 18 Years | 80 Years | Female | 0 | Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | JPRN-UMIN000006387 | 2011/11/01 | 31/10/2011 | Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis | interstitital cystitis | Intravesical instillation of heparin, lidocain and bicarbonate | University of Tokushima | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Phase 2 | Japan | |
7 | NCT00256542 (ClinicalTrials.gov) | January 2006 | 17/11/2005 | Study of U101 for Bladder Pain and/or Urgency | A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin | Pelvic Pain;Interstitial Cystitis;Bladder Diseases | Drug: Alkalinized Lidocaine-Heparin | Urigen | NULL | Completed | 18 Years | N/A | Both | 90 | Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03306836 (ClinicalTrials.gov) | September 2016 | 31/5/2017 | Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 | Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation | Cerebral Aneurysm;Arteriovenous Malformations | Drug: Heparin Sodium | Beijing Tiantan Hospital | Tang-Du Hospital;Kunming Medical University;First Affiliated Hospital of Fujian Medical University;Nanjing PLA General Hospital;Fujian Medical University Union Hospital | Recruiting | N/A | 70 Years | All | 408 | N/A | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2007-006276-11-IT (EUCTR) | 18/05/2010 | 07/05/2010 | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - ND | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - ND | Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763 | Product Name: heparin 25mg inhalation powder, hard capsule Product Code: VR496 | VECTURA LIMITED | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 1;Phase 2 | Ireland;Italy | ||
2 | EUCTR2007-006276-11-IE (EUCTR) | 11/11/2008 | 11/02/2008 | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in adults with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in adults with Cystic Fibrosis | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in adults with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in adults with Cystic Fibrosis | Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung | Product Name: Heparin 25mg inhalation powder, hard capsule INN or Proposed INN: HEPARIN SODIUM | Vectura Limited | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 1;Phase 2 | Ireland;Italy | ||
3 | EUCTR2007-006276-11-GB (EUCTR) | 01/09/2008 | 26/11/2007 | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis | Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung | Product Name: Heparin 25mg inhalation powder, hard capsule INN or Proposed INN: HEPARIN SODIUM | Vectura Limited | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 1;Phase 2 | Ireland;Italy;United Kingdom | ||
4 | EUCTR2007-006276-11-PL (EUCTR) | 06/05/2009 | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis | A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis | Cystic Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung | Product Name: Heparin 25mg inhalation powder, hard capsule INN or Proposed INN: HEPARIN SODIUM | Vectura Limited | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | Poland;Ireland;Italy;United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02517307 (ClinicalTrials.gov) | February 2016 | 2/7/2015 | Fatty Acid Oxidation Defects and Insulin Sensitivity | Role of Fatty Acid Oxidation Defects in Insulin Sensitivity | Very Long-chain Acyl-CoA Dehydrogenase Deficiency;Trifunctional Protein Deficiency;Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Medium-chain Acyl-CoA Dehydrogenase Deficiency;Normal Volunteers;Carnitine Palmitoyltransferase II Deficiency, Myopathic | Drug: Intralipid/Heparin;Drug: Glycerol/Saline;Drug: Hyperinsulinemic euglycemic clamp | Oregon Health and Science University | NULL | Recruiting | 18 Years | N/A | All | 50 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02517307 (ClinicalTrials.gov) | February 2016 | 2/7/2015 | Fatty Acid Oxidation Defects and Insulin Sensitivity | Role of Fatty Acid Oxidation Defects in Insulin Sensitivity | Very Long-chain Acyl-CoA Dehydrogenase Deficiency;Trifunctional Protein Deficiency;Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Medium-chain Acyl-CoA Dehydrogenase Deficiency;Normal Volunteers;Carnitine Palmitoyltransferase II Deficiency, Myopathic | Drug: Intralipid/Heparin;Drug: Glycerol/Saline;Drug: Hyperinsulinemic euglycemic clamp | Oregon Health and Science University | NULL | Recruiting | 18 Years | N/A | All | 50 | N/A | United States |